Related Experiment Video
Updated: Jul 14, 2026
11:25
Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
In vitro methotrexate as a practical approach to selective allodepletion
Atul Sathe1, Sterling B Ortega, Dorothy I Mundy
1Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9072, USA.
Summary
Methotrexate selectively depletes alloreactive T cells, offering a potential strategy to prevent graft-versus-host disease (GVHD) after stem cell transplantation while preserving beneficial immune functions.
Area of Science:
- Immunology
- Transplantation immunology
- Cellular immunology
Background:
- Graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT).
- GVHD pathogenesis involves alloreactive donor T cells, making their selective removal a therapeutic target.
- Preserving beneficial T cell functions like graft survival and anti-leukemia effects is crucial.
Purpose of the Study:
- To investigate the efficacy of methotrexate in selectively depleting alloreactive T cells.
- To assess methotrexate's potential in preventing GVHD in vitro.
Main Methods:
- Utilized HLA-mismatched mixed lymphocyte reactions (MLR) to model alloreactivity.
- Treated cells with methotrexate, a clinically approved antimetabolite.
- Evaluated T cell proliferation and immune responses upon re-stimulation.
Main Results:
- Methotrexate inhibited alloreactive T cell proliferation in primary MLR.
- Methotrexate-treated cells showed reduced alloreactive responses upon secondary stimulation.
- Responses to third-party antigens and viral antigens remained largely preserved.
Conclusions:
- In vitro methotrexate treatment achieves specific allodepletion of T cells.
- Methotrexate demonstrates preclinical potential as an agent for GVHD prevention.
- This approach may help maintain crucial T cell-mediated graft benefits.
